Affinage

CHRFAM7A

CHRNA7-FAM7A fusion protein · UniProt Q494W8

Length
412 aa
Mass
46.2 kDa
Annotated
2026-06-09
54 papers in source corpus 19 papers cited in narrative 20 extracted findings
Cross-family judge faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CHRFAM7A encodes dupα7, a human-specific, truncated α7 nicotinic acetylcholine receptor subunit that co-assembles with full-length α7 (CHRNA7) to act as a dominant-negative modulator of α7nAChR function (PMID:21718690, PMID:21047781). dupα7 yields protein but no functional receptor on its own; co-expression with α7 reduces ACh- and nicotine-evoked currents dose-dependently while sparing α-bungarotoxin binding, indicating formation of ACh-silent heteromers and reduced trafficking of functional α7 to the membrane (PMID:21718690, PMID:21047781). The resulting CHRFAM7A/α7 receptor behaves as a hypomorphic channel with reduced Ca2+ influx and a prolonged closed state, shifting the Ca2+ reservoir toward the endoplasmic reticulum and activating the small GTPase Rac1, which reorganizes the actin cytoskeleton to control monocyte/macrophage adhesion, motility, phagocytosis, and mechanosensation (PMID:38569318). This dominant-negative reduction of α7nAChR-mediated calcium signaling is conserved in human iPSC-derived neurons and mouse transgenic neurons and is detectable in vivo at the neuromuscular junction (PMID:30308236, PMID:39073048). Because α7nAChR signaling restrains inflammation, CHRFAM7A reshapes immune output: it biases hematopoietic differentiation toward inflammatory monocytes and modulates leukocyte mobilization in systemic inflammation (PMID:30944217, PMID:37655479), and in macrophages it weakens cholinergic anti-inflammatory tone, producing exaggerated pro-inflammatory cytokine responses (PMID:37655479). CHRFAM7A transcription is controlled independently of CHRNA7 by a unique 1-kb 5'-UTR promoter that is strongly responsive to LPS, with NF-κB mediating its down-regulation in monocytes/macrophages (PMID:25860877, PMID:25681457, PMID:20926142). CHRFAM7A overexpression also remodels focal-adhesion and transepithelial-migration gene programs and reduces monocyte migration, chemotaxis, and anchorage-independent growth (PMID:25860877, PMID:32303780).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2010 High

    Established that the duplicate gene product dupα7 is natively translated but cannot form functional receptors alone, and acts dominant-negatively when combined with α7 — defining its core molecular behavior.

    Evidence Xenopus oocyte electrophysiology with dose-response, α-bungarotoxin binding, and confocal imaging of membrane receptors, plus native expression in HL-60/macrophages

    PMID:21047781

    Open questions at the time
    • Stoichiometry of the heteromer not resolved
    • Mechanism of reduced membrane trafficking not defined at the molecular level
  2. 2011 High

    Confirmed in independent systems that co-assembly produces ACh-silent heteromers retaining toxin binding, and that an allosteric modulator can partially rescue function — refining the dominant-negative model as one of altered gating rather than absent receptor.

    Evidence Functional electrophysiology in oocytes and cell lines, I-BTX radioligand binding, and PNU-120596 pharmacological rescue

    PMID:21718690

    Open questions at the time
    • Did not establish receptor structure or subunit arrangement
    • Physiological consequence in native cells not addressed
  3. 2011 Medium

    Identified how CHRFAM7A expression is regulated independently of CHRNA7, showing transcriptional suppression by inflammatory signaling.

    Evidence Real-time PCR, Western blotting, and parthenolide inhibition in THP-1 monocytes implicating NF-κB

    PMID:20926142

    Open questions at the time
    • NF-κB binding to the promoter not shown directly
    • Inhibitor-based, single cell line
  4. 2015 Medium

    Mapped a unique 1-kb 5'-UTR promoter as the basis for autonomous, LPS-responsive regulation of CHRFAM7A and linked its overexpression to focal-adhesion and migration gene programs.

    Evidence Promoter/luciferase mapping, stable overexpression with gene expression profiling, flow cytometry of surface α-bungarotoxin binding in THP-1 and gut epithelial cells

    PMID:25681457 PMID:25860877

    Open questions at the time
    • Direct transcription factors binding the 1-kb element not identified
    • Mechanism by which CHRFAM7A upregulates CHRNA7 unexplained
  5. 2018 Medium

    Demonstrated that CHRFAM7A interferes with α7nAChR ligand binding not only in vitro but in vivo, extending the dominant-negative effect to intact tissue including the neuromuscular junction.

    Evidence Stable transfection of PC12 cells and CHRFAM7A-transgenic mice; α-BTX binding by immunohistochemistry and flow cytometry

    PMID:30308236

    Open questions at the time
    • Functional consequence at the NMJ not measured
    • Single lab
  6. 2019 High

    Connected the receptor-level defect to immune-system outcomes, showing CHRFAM7A biases hematopoiesis toward monocytes and alters immune cell mobilization in systemic inflammation.

    Evidence CHRFAM7A-transgenic mice with HSC quantification, in vitro differentiation, and a SIRS model with lung immune cell flow cytometry

    PMID:30944217

    Open questions at the time
    • Cell-intrinsic vs systemic contribution to HSC bias not separated
    • Direct link from Ca2+/Rac1 signaling to differentiation not yet shown here
  7. 2019 Medium

    Tested CHRFAM7A function in human neurons with defined copy number, linking dosage to receptor desensitization and to modulation of amyloid-beta handling and neuronal cytokine output.

    Evidence iPSC-derived neurons (0 vs 1 copy), electrophysiology, Aβ1-42 uptake assay, cytokine measurement

    PMID:30710073

    Open questions at the time
    • Mechanism of inflammasome-independent IL-1β/TNF-α activation undefined
    • Supra-physiological Aβ concentrations used
  8. 2020 Medium

    Showed direct CHRFAM7A control of monocyte migratory and proliferative behavior, and that allelic orientation (direct vs inverted) yields distinct functional phenotypes with clinical pharmacogenetic relevance.

    Evidence Lentiviral overexpression with Transwell migration, chemotaxis, and soft-agar assays; iPSC electrophysiology and Aβ assays with double-blind AChEI pharmacogenetic analysis

    PMID:32303780 PMID:32818803

    Open questions at the time
    • Molecular mediators of reduced migration not pinpointed
    • Clinical association is correlative
  9. 2024 High

    Resolved the downstream signaling chain, showing the hypomorphic receptor reshapes calcium dynamics (ER reservoir shift) to activate Rac1 and reorganize actin, mechanistically linking channel function to adhesion, motility, phagocytosis, and mechanosensation.

    Evidence Ca2+ imaging, electrophysiology, Rac1 activation assay, actin imaging, and phagocytosis assays in iPSC-derived cells and primary monocytes

    PMID:38569318

    Open questions at the time
    • Coupling between ER Ca2+ shift and Rac1 GEF activation not molecularly defined
    • Whether the same pathway operates in non-immune cells untested
  10. 2024 High

    Confirmed the dominant-negative calcium phenotype across multiple agonists in two independent neuronal systems, solidifying generality of the functional effect.

    Evidence Fura-2 calcium imaging with three α7 ligands plus PAM in hiPSC-derived cortical neurons and SCG neurons from transgenic mice

    PMID:39073048

    Open questions at the time
    • Neuronal behavioral/circuit consequence not addressed

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the structural basis of subunit stoichiometry, the molecular link between ER calcium redistribution and Rac1 activation, and CHRFAM7A's role in human cortical development converge to produce its immune and neuronal phenotypes remains unresolved.
  • No experimental structure of the dupα7/α7 heteromer
  • Direct GEF coupling Ca2+ to Rac1 unidentified
  • Developmental role rests on preprint and is not cleanly separated from CHRNA7

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 3 GO:0005198 structural molecule activity 2 GO:0005215 transporter activity 2
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-168256 Immune System 2 R-HSA-112316 Neuronal System 1 R-HSA-162582 Signal Transduction 1
Partners
CHRNA7RAC1
Complex memberships
α7 nicotinic acetylcholine receptor heteropentamer (dupα7/α7)

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 CHRFAM7A (dupα7) expressed alone yields protein but no functional receptor. Co-expression with α7 (CHRNA7) in cell lines and Xenopus oocytes causes significant reduction in ACh-evoked current amplitude without a proportional reduction in α-bungarotoxin (I-BTX) binding, indicating formation of non-functional (ACh-silent) heteromeric receptors. The allosteric modulator PNU-120596 produced a larger increase in ACh-evoked current in cells co-expressing the duplicate than in controls, consistent with a dominant-negative modulation mechanism. Functional electrophysiology in Xenopus oocytes and cell lines; I-BTX radioligand binding; pharmacological rescue with PNU-120596 Biochemical pharmacology High 21718690
2010 dupα7 (CHRFAM7A protein) is natively translated in HL-60 cells. Injection of dupα7 mRNA alone into Xenopus oocytes fails to generate functional receptors. Co-injection with α7 mRNA reduces nicotine-evoked α7 currents in a dose-dependent manner (up to 94% reduction at 1:10 α7:dupα7 ratio). This dominant-negative effect is primarily due to reduction in the number of functional α7 receptors reaching the oocyte membrane, as confirmed by α-bungarotoxin binding and fluorescent confocal assays. dupα7 mRNA levels in macrophages are higher than α7 mRNA levels and are down-regulated by IL-1β, LPS, and nicotine. Xenopus oocyte electrophysiology; α-bungarotoxin binding; fluorescent confocal imaging of membrane receptors; RT-PCR in native cells The Journal of biological chemistry High 21047781
2015 CHRFAM7A has a unique 1-kb promoter sequence in its 5'-UTR that independently regulates its expression separately from CHRNA7. Stable CHRFAM7A overexpression in THP1 cells alters cell phenotype and modifies expression of genes associated with focal adhesion (FAK, PI3K, Akt, rho, GEF, Elk1, CycD), leukocyte transepithelial migration (Nox, ITG, MMPs, PKC), and cancer pathways. Unexpectedly, stable CHRFAM7A overexpression upregulates CHRNA7, leading to increased α-bungarotoxin binding on THP1 cell surface. Promoter mapping; stable transfection; gene expression profiling; flow cytometry with α-bungarotoxin binding Molecular medicine (Cambridge, Mass.) Medium 25860877
2015 CHRFAM7A is expressed in human gut epithelial cells. A 3-hour treatment with 100 ng/ml LPS increases CHRFAM7A gene expression by ~1000-fold in gut epithelial cells while having little effect on CHRNA7 expression. A 1-kb sequence in the CHRFAM7A 5'-UTR is identified as a regulatory element responsive to LPS. RT-PCR in gut epithelial cell lines; luciferase-based promoter mapping; LPS stimulation assay FASEB journal Medium 25681457
2011 In THP-1 monocytic cells, CHRFAM7A (α7dup) mRNA and protein are down-regulated upon LPS challenge. This transcriptional down-regulation is mediated by NF-κB, as the specific NF-κB inhibitor parthenolide prevents the reduction in α7dup transcript. Real-time PCR; Western blotting; pharmacological inhibition with parthenolide Journal of neuroimmunology Medium 20926142
2019 CHRFAM7A blocks ligand binding to both mouse and human α7nAChR. In CHRFAM7A-transgenic mice, CHRFAM7A increased the hematopoietic stem cell (HSC) reservoir in bone marrow and biased HSC differentiation toward the monocyte lineage in vitro. In a SIRS model, HSCs were spared in CHRFAM7A-transgenic mice while depleted in wild-type; transgenic mice also showed increased immune cell mobilization and a shift to inflammatory monocytes from granulocytes in inflamed lungs. CHRFAM7A-transgenic mouse model; ligand binding assay; bone marrow HSC quantification; in vitro HSC differentiation assay; SIRS model with flow cytometry of lung immune cells Proceedings of the National Academy of Sciences of the United States of America High 30944217
2019 In iPSC-derived neurons harboring CHRFAM7A (1 copy vs. 0 copy), PNU-modulated desensitization of α7nAChR currents increased as a function of CHRFAM7A dosage. CHRFAM7A mitigated the dose-response of amyloid-beta (Aβ1-42) uptake, suggesting a protective effect at supra-physiological Aβ concentrations. In the presence of CHRFAM7A, Aβ1-42 uptake activated neuronal IL-1β and TNF-α without activating the canonical inflammasome pathway. iPSC-derived neurons with defined CHRFAM7A copy number; electrophysiology; Aβ1-42 uptake assay; cytokine measurement Translational psychiatry Medium 30710073
2018 CHRFAM7A expression in rat PC12 cells and CHRFAM7A-transgenic mice decreases α-bungarotoxin (α-BTX) binding to α7nAChR, as detected by immunohistochemistry and flow cytometry. In vivo, α-BTX co-staining with neurofilament at the neuromuscular junction was decreased in CHRFAM7A-transgenic mice compared to wild-type, demonstrating that CHRFAM7A interferes with α7nAChR ligand binding in vivo. Stable transfection of rat PC12 cells; α-BTX binding by immunohistochemistry and flow cytometry; CHRFAM7A-transgenic mouse neuromuscular junction staining Neuroscience letters Medium 30308236
2020 CHRFAM7A overexpression in THP-1 human monocytic cells reduces cell migration, reduces chemotaxis to monocyte chemoattractant protein, and reduces colony formation in soft agar, demonstrating a direct role in regulating monocyte/macrophage migratory and proliferative behavior. Lentiviral gene delivery; Transwell migration assay; chemotaxis assay; soft agar colony formation assay Inflammation research Medium 32303780
2020 The direct and inverted CHRFAM7A alleles have distinct functional phenotypes with respect to α7nAChR electrophysiology and Aβ neurotoxicity in iPSC models. Functional CHRFAM7A allele classifies the population as ~25% non-carriers and ~75% carriers, and carrier status modifies AChEI therapy response in Alzheimer's disease patients. iPSC electrophysiology; Aβ uptake assay; double-blind pharmacogenetic clinical analysis EBioMedicine Medium 32818803
2021 CHRFAM7A overexpression in OGD/R-treated microglia inhibited NLRP3 inflammasome activation and cell pyroptosis via the NLRP3/Caspase-1 pathway, and promoted polarization of microglia from M1 to M2 phenotype, thereby attenuating inflammatory injury. CHRFAM7A overexpression in OGD/R microglia model; NLRP3/Caspase-1 pathway activation assay; pyroptosis markers; M1/M2 phenotype markers (iNOS, Arg1) Inflammation Low 33405023
2022 In CHRFAM7A-transgenic mice, OA was more severe and mechanical allodynia was greater than in WT mice in the destabilization of medial meniscus model, associated with decreased suppression of inflammation by α7nAChR agonist. Transgenic mice showed higher basal sensitivity to pain stimuli and increased pain behavior in monoiodoacetate and formalin models. Dorsal root ganglia of transgenic mice showed increased macrophage infiltration and expression of fractalkine chemokine. Human chondrocytes with two CHRFAM7A copies had reduced anti-inflammatory response to nicotine. CHRFAM7A-transgenic mouse OA model; mechanical allodynia testing; pain behavior assays; DRG immunostaining; human chondrocyte culture with nicotine treatment Annals of the rheumatic diseases Medium 36627169
2024 CHRFAM7A/α7nAChR functions as a hypomorphic receptor with mitigated Ca2+ influx and prolonged channel closed state compared to α7nAChR alone. This shifts the Ca2+ reservoir from extracellular space to the endoplasmic reticulum (ER), altering Ca2+ dynamics. The Ca2+ decoder small GTPase Rac1 is activated downstream, reorganizing the actin cytoskeleton and driving phenotypes including cellular adhesion, motility, phagocytosis, and tissue mechanosensation in iPSC-derived and primary monocyte models. Ca2+ imaging in iPSC-derived cells and primary monocytes; electrophysiology; Rac1 activation assay; actin cytoskeleton imaging; phagocytosis assay EBioMedicine High 38569318
2024 CHRFAM7A (dupα7) reduces α7nAChR-mediated calcium transients in response to multiple agonists (PNU282987, choline, 4BP-TQS) in hiPSC-derived cortical neurons and in SCG neurons from CHRFAM7A-transgenic mice, confirming dominant-negative reduction of α7nAChR function in neuronal cells. Fura-2 calcium imaging in hiPSC-derived cortical neurons and SCG neurons from transgenic mice; three different α7-specific ligands with PAM II PNU120596 The European journal of neuroscience High 39073048
2021 Computational structural modeling of all possible dupα7/α7 pentameric combinations showed that receptors comprising four or more dupα7 subunits are not stable enough to form a functional ion channel. Models with dupα7/α7 interfaces are more stable and less detrimental to ion conductance than dupα7/dupα7 interfaces. The optimal stoichiometry for functional pentamers should include no more than three dupα7 monomers, favoring a dupα7/α7 interface. Receptors bearing dupα7 subunits are less sensitive to Aβ42 by protein-protein docking analysis. Atomistic molecular dynamics simulations; coarse-grain simulations; free energy calculations for Ca2+ conductance; protein-protein docking with α-bungarotoxin and Aβ42 International journal of molecular sciences Low 34067314
2022 CHRFAM7A overexpression in HK-2 human renal tubular epithelial cells inhibited TGF-β1-induced epithelial-mesenchymal transition (EMT) and suppressed activation of the TGF-β1/Smad2/3 signaling pathway in vitro. In CHRFAM7A-transgenic mice subjected to UUO injury, transgenic overexpression decreased fibrotic gene expression, collagen deposition, TGF-β1 and Smad2/3 expression, and inflammatory cytokine release. CHRFAM7A overexpression in HK-2 cells; TGF-β1 stimulation; EMT marker quantification; Smad2/3 pathway activation assay; CHRFAM7A-transgenic mouse UUO model Journal of cellular and molecular medicine Medium 36479618
2020 CHRFAM7A overexpression in a hypertrophic scar mouse model increased activation of the Notch pathway, which attenuated M2 macrophage polarization and increased M1 macrophages in the initial period, decreasing scar fibrosis. Lentiviral CHRFAM7A overexpression in mouse hypertrophic scar model; macrophage phenotype quantification (M1/M2); Notch pathway analysis; fibrosis assessment Biomedicine & pharmacotherapy Low 32890966
2019 CHRFAM7A CHRFAM7A gene expression in CHRFAM7A-transgenic mouse brain significantly modulated proteins involved in signaling pathways of α7nAChR-mediated neuropsychiatric disorders (Parkinson's, Alzheimer's, Huntington's disease, and alcoholism) as assessed by iTRAQ-2D-LC-MS/MS proteomic profiling. CHRFAM7A-transgenic mouse brain; iTRAQ-2D-LC-MS/MS proteomics; bioinformatics pathway analysis Gene Low 31348980
2023 CHRFAM7A transgenic mouse peritoneal macrophages exhibited decreased ligand-binding capability (reduced α7nAChR agonist binding) and an activated pro-inflammatory cytokine gene expression profile at basal state. When challenged with LPS, macrophages from transgenic mice showed an exaggerated pro-inflammatory response at earlier time points and lower LPS dosages compared to wild-type. Leukocyte mobilization and pro-inflammatory cytokine levels were significantly higher in transgenic mice at the early stage of sepsis. CHRFAM7A-transgenic mouse peritoneal macrophages; ligand binding assay; LPS stimulation; cytokine measurement; sepsis model with survival analysis Cell biology international Medium 37655479
2025 CHRFAM7A is expressed in SOX2+ progenitors and neurons in the developing human cortex, with particular enrichment along radial glia (RG) endfeet. nAChR activation increases RG proliferation while decreasing neuronal differentiation; knockdown reduces RG and increases neurons. Single-cell RNA-seq reveals that CHRNA7 and CHRFAM7A selectively modulate different gene changes in excitatory neurons upon nicotine exposure. YAP1 is identified as a downstream effector of nAChR signaling; YAP1 inhibition reverses nicotine-induced phenotypic alterations in outer RG cells. Organotypic slice cultures; dissociated cultures; nAChR knockdown; single-cell RNA sequencing; YAP1 inhibition experiments bioRxivpreprint Low

Source papers

Stage 0 corpus · 54 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function. Neuropharmacology 147 25701707
2011 The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR function. Biochemical pharmacology 111 21718690
2010 Function of partially duplicated human α77 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response. The Journal of biological chemistry 111 21047781
2014 miR-224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma. Journal of gastroenterology and hepatology 83 24219032
2009 A 2-base pair deletion polymorphism in the partial duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is associated with schizophrenia. Brain research 78 19631623
2006 Association study of CHRFAM7A copy number and 2 bp deletion polymorphisms with schizophrenia and bipolar affective disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 66 16823804
2011 Expression of the α7 nAChR subunit duplicate form (CHRFAM7A) is down-regulated in the monocytic cell line THP-1 on treatment with LPS. Journal of neuroimmunology 55 20926142
2014 CHRFAM7A, a human-specific and partially duplicated α7-nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury. Journal of leukocyte biology 45 25473097
2021 CHRFAM7A Overexpression Attenuates Cerebral Ischemia-Reperfusion Injury via Inhibiting Microglia Pyroptosis Mediated by the NLRP3/Caspase-1 pathway. Inflammation 43 33405023
2015 A Human-Specific α7-Nicotinic Acetylcholine Receptor Gene in Human Leukocytes: Identification, Regulation and the Consequences of CHRFAM7A Expression. Molecular medicine (Cambridge, Mass.) 36 25860877
2019 Effect of donepezil on the expression and responsiveness to LPS of CHRNA7 and CHRFAM7A in macrophages: A possible link to the cholinergic anti-inflammatory pathway. Journal of neuroimmunology 35 31048268
2019 Uniquely human CHRFAM7A gene increases the hematopoietic stem cell reservoir in mice and amplifies their inflammatory response. Proceedings of the National Academy of Sciences of the United States of America 33 30944217
2015 CHRFAM7A: a human-specific α7-nicotinic acetylcholine receptor gene shows differential responsiveness of human intestinal epithelial cells to LPS. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 29 25681457
2021 Gene Therapy Using Adeno-Associated Virus Serotype 8 Encoding TNAP-D10 Improves the Skeletal and Dentoalveolar Phenotypes in Alpl-/- Mice. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 27 34076297
2022 The Human-Restricted Isoform of the α7 nAChR, CHRFAM7A: A Double-Edged Sword in Neurological and Inflammatory Disorders. International journal of molecular sciences 25 35408823
2020 Europium(III) Photoluminescence Governed by d8-d10 Heterometallophilic Interactions in Trimetallic Cyanido-Bridged Coordination Frameworks. Inorganic chemistry 24 31909606
2020 CHRFAM7A: A human specific fusion gene, accounts for the translational gap for cholinergic strategies in Alzheimer's disease. EBioMedicine 23 32818803
2019 iPSC model of CHRFAM7A effect on α7 nicotinic acetylcholine receptor function in the human context. Translational psychiatry 23 30710073
2016 Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease. BBA clinical 23 27051591
2019 Association of a Functional Polymorphism in the CHRFAM7A Gene with Inflammatory Response Mediators and Neuropathic Pain after Spinal Cord Injury. Journal of neurotrauma 19 30924722
2015 Expression of CHRFAM7A and CHRNA7 in neuronal cells and postmortem brain of HIV-infected patients: considerations for HIV-associated neurocognitive disorder. Journal of neurovirology 19 26567012
2023 Human-specific duplicate CHRFAM7A gene is associated with more severe osteoarthritis and amplifies pain behaviours. Annals of the rheumatic diseases 18 36627169
2022 Gene Therapy Using Recombinant AAV Type 8 Vector Encoding TNAP-D10 Improves the Skeletal Phenotypes in Murine Models of Osteomalacia. JBMR plus 17 36699639
2020 Human-specific gene CHRFAM7A mediates M2 macrophage polarization via the Notch pathway to ameliorate hypertrophic scar formation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 17 32890966
2018 CHRFAM7A alters binding to the neuronal alpha-7 nicotinic acetylcholine receptor. Neuroscience letters 17 30308236
1999 UVRR Spectroscopy and Vibrational Analysis of Mercury Thiolate Compounds Resembling d(10) Metal Binding Sites in Proteins. Inorganic chemistry 17 11671099
2019 Global proteomic profiling of the uniquely human CHRFAM7A gene in transgenic mouse brain. Gene 15 31348980
2013 Association study of the 2-bp deletion polymorphism in exon 6 of the CHRFAM7A gene with idiopathic generalized epilepsy. DNA and cell biology 15 24024466
2008 Differentiating nicotine- versus schizophrenia-associated decreases of the alpha7 nicotinic acetylcholine receptor transcript, CHRFAM7A, in peripheral blood lymphocytes. Journal of neural transmission (Vienna, Austria : 1996) 15 19082523
2020 CHRFAM7A reduces monocyte/macrophage migration and colony formation in vitro. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 14 32303780
2015 Synthesis and characterization of substituted Schiff-base ligands and their d(10) metal complexes: structure-induced luminescence tuning behaviors and applications in co-sensitized solar cells. Dalton transactions (Cambridge, England : 2003) 13 25597537
1993 In vitro immunization of mouse spleen cells for the production of monoclonal IgG1 antibodies using an antigen-specific T helper cell clone (D.10.G4.1). Journal of immunological methods 12 7507145
2018 Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment. European journal of human genetics : EJHG 11 30089821
2011 Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297. Applied immunohistochemistry & molecular morphology : AIMM 11 21030862
2008 Preferential formation of homochiral helical sandwich-shaped architectures through the metal-mediated assembly of tris(imidazoline) ligands with a set of d(3)-d(10) transition-metal ions. Chemistry (Weinheim an der Bergstrasse, Germany) 11 19016554
2017 Human-specific CHRFAM7A protects against radiotherapy-induced lacrimal gland injury by inhibiting the p38/JNK signalling pathway and oxidative stress. International journal of clinical and experimental pathology 10 31966770
2022 Polymorphisms in alpha 7 nicotinic acetylcholine receptor gene, CHRNA7, and its partially duplicated gene, CHRFAM7A, associate with increased inflammatory response in human peripheral mononuclear cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 9 35344211
2024 Translational implications of CHRFAM7A, an elusive human-restricted fusion gene. Molecular psychiatry 8 38200291
2022 Up-regulation of the human-specific CHRFAM7A gene protects against renal fibrosis in mice with obstructive nephropathy. Journal of cellular and molecular medicine 8 36479618
2021 Effect of CHRFAM7A Δ2bp gene variant on secondary inflammation after spinal cord injury. PloS one 8 33956875
2009 CHRFAM7A copy number and 2-bp deletion polymorphisms and antisaccade performance. The international journal of neuropsychopharmacology 8 19149910
1996 Mono- and Dinuclear d(10) Metal Complexes of Hexakis(3,5-dimethylpyrazolyl)cyclotriphosphazene. Synthesis, Structures, and Unusual Solution Dynamic Behavior. Inorganic chemistry 8 11666593
2021 CHRFAM7A expression in mice increases resiliency after injury. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 7 34792616
2011 Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. Journal of clinical bioinformatics 6 21961533
2023 Unanswered questions in the regulation and function of the duplicated α7 nicotinic receptor gene CHRFAM7A. Pharmacological research 5 37164281
2023 GTS-21 Enhances Regulatory T Cell Development from T Cell Receptor-Activated Human CD4+ T Cells Exhibiting Varied Levels of CHRNA7 and CHRFAM7A Expression. International journal of molecular sciences 5 37569633
2021 Structure, Dynamics, and Ligand Recognition of Human-Specific CHRFAM7A (Dupα7) Nicotinic Receptor Linked to Neuropsychiatric Disorders. International journal of molecular sciences 5 34067314
2024 CHRFAM7A diversifies human immune adaption through Ca2+ signalling and actin cytoskeleton reorganization. EBioMedicine 4 38569318
2022 Expression of the α7 nAChR Subunit Duplicate Form (CHRFAM7A) Was Down-Regulated in Patients with Intracranial Infection and Reduced Inflammation in in vitro Model by p38 MAPK. Neuroimmunomodulation 4 35100606
2023 Effects of Different Exercise Types on Chrna7 and Chrfam7a Expression in Healthy Normal Weight and Overweight Type 2 Diabetic Adults. Biomedicines 2 36831101
2023 Human-specific CHRFAM7A primes macrophages for a heightened pro-inflammatory response at the earlier stage of inflammation. Cell biology international 2 37655479
2024 Human restricted CHRFAM7A gene increases brain efficiency. Frontiers in neuroscience 1 38711941
2024 The human-specific nicotinic receptor subunit CHRFAM7A reduces α7 receptor function in human induced pluripotent stem cells-derived and transgenic mouse neurons. The European journal of neuroscience 1 39073048
2026 Identification of a novel fiber shaft structural motif and overexpression of key transcripts elucidated in human adenovirus D 10. PLoS pathogens 0 42048387

Missed literature

Know a paper Affinage missed for CHRFAM7A? Flag it for the maintainers and the community.

No submissions yet.